Mirum Pharmaceuticals Inc. - notizie pubblicate 221 - letture 2.963
MIRUM PHARMACEUTICALS INC.
Current Report - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Provides Development Program Updates
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm), today announced the decision to discontinue the ohana study of volixibat in intrahepatic cholesta ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm), a biopharmaceutical company focused on the identification, acquisition, development and commercia ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
- net product sales for livmarli® (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - mirum raises 2022 full year net p ...
MIRUM PHARMACEUTICALS INC.
Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer mirum pharmaceutical ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that it will report third quarter financial results on wednesday, november 9, 2022 ...
MIRUM PHARMACEUTICALS INC.
Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases
Phase 3 march pfic study to be presented as oral late-breaker rise infant safety study in algs to be presented as late-breaker poster foster city, calif.--(business wire)-- mirum p ...
MIRUM PHARMACEUTICALS INC.
Positive Topline Data Announced from Mirum's LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) - Form 8-K
Positive topline data announced from mirum's livmarli phase 3 march study in progressive familial intrahepatic cholestasis (pfic) • met primary endpoint (p=0.0098); highly statis ...
MIRUM PHARMACEUTICALS INC.
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
Met primary endpoint (p=0.0098); highly statistically significant effects in all pfic subtypes. significant improvements in total bilirubin and growth versus placebo at six months. ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics
Foster city, calif.--(business wire)-- mirum pharmaceuticals, inc. (nasdaq: mirm) today announced that data highlighting quality of life and sleep improvements from its pivotal ico ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti